



Positive preclinical data presented for SVF's candidate immunotherapy SVF-001 against chronic hepatitis B and D

Stockholm, Sweden – October 24, 2025 SVF Vaccines AB, a biotechnology company developing next-generation vaccines, announces positive data on the company's SVF-001 immunotherapy against chronic hepatitis B (HBV) and D (HDV) virus infections. The results were presented by SVF Vaccines' CSO and co-founder, Professor Matti Sällberg, at the Molecular Biology of HBV meeting on September 11 in Berlin and at the DeltaCure meeting on October 10 in Hannover.

The preclinical study showed that antibodies from SVF-001-immunized mice exerted a clear therapeutic effect when used to treat chronic HBV/HDV coinfection in mice with humanized livers. The treatment resulted in deep reductions of HBV DNA and HDV RNA levels in blood.

The antiviral effect of the immunotherapy in this humanized mouse model represents a correlate to the outcome SVF Vaccines would aim to achieve in patients with chronic HBV and HDV coinfection.

“These data represent a clear demonstration that SVF-001 induces antibodies that control HBV and HDV infection. They therefore provide strong support that this product has the potential to provide a stable immunological control of these infections, a so-called functional cure, in patients who are chronically infected with HBV and HDV” says SVF's chairman of the board, John Öhd.

For further information, please contact:

John Öhd, Chairman of the Board, SVF Vaccines AB

Phone: +46 (0) 70 766 80 97, e-mail: john.ohd@karolinskadevelopment.com

About SVF Vaccines

SVF Vaccines AB is a Swedish biotechnology company developing next-generation DNA vaccines and immunotherapies based on proprietary technology originating from Karolinska Institutet. The company's portfolio includes SVF-001, a therapeutic immunotherapy for chronic hepatitis B and D, and SVF-002, a universal prophylactic vaccine against COVID-19, as well as early-stage discovery programs for other serious infectious diseases.